CoChat

An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder

Lewis-Fernández, Roberto, Lam, Peter, Lucak, Susan, Galfalvy, Hanga, Jackson, Elizabeth, Fried, Jane, Rosario, Melissa, de la Cruz, Ana Alicia, Sánchez-Lacay, Arturo, Díaz, Samantha, Schneier, Franklin · 2016 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Major depressive disorder (MDD) and irritable bowel syndrome (IBS) frequently co-occur, yet treating their comorbid presentation is challenging. Low-dose tricyclic antidepressants are efficacious for IBS, but higher doses to treat depressive symptoms present tolerability problems, whereas selective serotonin reuptake inhibitors are more tolerable but show inconsistent efficacy for IBS. If efficacious, serotonin-norepinephrine reuptake inhibitors like duloxetine would provide a useful alternative. We explored efficacy, tolerability, and time to onset of action of duloxetine in comorbid IBS-MDD in an open-label, 12-week trial. Repeated-measures mixed-effects regression analysis with the intent-to-treat sample assessed rate of change of the clinician-administered Gastrointestinal Symptoms Rating Scale, Montgomery-Åsberg Depression Rating Scale, and other clinician-administered and self-report scales. Seventeen Hispanic adults with current MDD and comorbid IBS meeting Rome III criteria entered the study. Medical and laboratory assessment ruled out alarm symptoms and signs inconsistent with IBS. Duloxetine led to significant improvement in Gastrointestinal Symptoms Rating Scale and Montgomery-Åsberg Depression Rating Scale scores and 71.4% and 64.3% intent-to-treat response rates for IBS and MDD, respectively. Abdominal pain severity decreased by 56%. Contrary to expectation of rapid analgesic effects, based on duloxetine studies for neuropathic pain, both IBS and MDD symptoms improved gradually; differences in slopes of improvement were nonsignificant. Duloxetine was moderately well tolerated at a mean endpoint dose of 60 mg/d. Study limitations include the lack of placebo control, modest sample size, single ethnic group, and high attrition rate. Duloxetine efficacy for comorbid IBS-MDD should be studied under placebo-controlled conditions with larger and more diverse samples.

Overview

Integrity signals

Registry

Crossref · 10.1097/jcp.0000000000000599

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Research works printed but not linked: 3

  1. 2001, Irritable bowel syndrome, anxiety, and depression: what are the links?, J Clin Psychiatry, 62, 38
  2. 2007, Antidepressants for neuropathic pain, Cochrane Database Syst Rev, 17
  3. 2010, A case of possible duloxetine-induced mania, Ger J Psychiatry, 13, 54

Cited by

See all 52

Metadata

Authors
Lewis-Fernández, R., Lam, P., Lucak, S., Galfalvy, H., Jackson, E., Fried, J., Rosario, M., de la Cruz, A. A., Sánchez-Lacay, A., Díaz, S., & Schneier, F.
Affiliations
  • From the *Department of Psychiatry, Columbia University; †New York State Psychiatric Institute; and ‡Weill Cornell Medicine, New York, NY.
  • Weill Cornell Medicine (US)
Corresponding author
  • Galfalvy, Hanga
  • Fried, Jane
  • Sánchez-Lacay, Arturo
  • Schneier, Franklin
Venue
Journal of Clinical Psychopharmacology
Published
2016-12
Volume
36
Issue
6
Pages
710-715
ISSN
  • 0271-0749 (ISSN-L)
  • 1533-712X
OpenAlex
W2537475627
Cited by
49
References
19
Citations by year
2026: 2 · 2025: 8 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 11 · 2020: 7 · 2019: 4 · 2018: 2 · 2017: 2
FWCI
2.91
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
duloxetine, irritable bowel syndrome, major depressive disorder, comorbidities, serotonin-norepinephrine reuptake inhibitors, abdominal pain, antidepressant tolerability, onset of action, Hispanic adults, Rome III criteria
MeSH terms
Duloxetine Hydrochloride, Serotonin and Noradrenaline Reuptake Inhibitors, Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Severity of Illness Index, Abdominal Pain, Treatment Outcome, Irritable Bowel Syndrome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder. https://app.cochat.ai/papers/10.1097/jcp.0000000000000599
The paper
Lewis-Fernández, R., Lam, P., Lucak, S., Galfalvy, H., Jackson, E., Fried, J., Rosario, M., de la Cruz, A. A., Sánchez-Lacay, A., Díaz, S., & Schneier, F. (2016). An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000599

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.